An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Public ClinicalTrials.gov record NCT06768671. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents Aged ≥12 to ≤17 Years at the Time of Study Inclusion With Active Moderate to Severe Hidradenitis Suppurativa
Study identification
- NCT ID
- NCT06768671
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- MoonLake Immunotherapeutics AG
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- Sonelokimab Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2024
- Primary completion
- Sep 27, 2026
- Completion
- Sep 27, 2026
- Last update posted
- May 5, 2026
2024 – 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site | North Little Rock | Arkansas | 72117 | — |
| Clinical Site | Stanford | California | 94304 | — |
| Clinical Site | Washington D.C. | District of Columbia | 20010 | — |
| Clinical Site | Hollywood | Florida | 33201 | — |
| Clinical Site | Miami | Florida | 33136 | — |
| Clinical Site | Macon | Georgia | 31217 | — |
| Clinical Site | Sandy Springs | Georgia | 30328 | — |
| Clinical Site | Chicago | Illinois | 60611 | — |
| Clinical Site | Columbus | Indiana | 47201 | — |
| Clinical Site | Murray | Kentucky | 42071 | — |
| Clinical Site | Waterford | Michigan | 48328 | — |
| Clinical Site | Fargo | North Dakota | 58103 | — |
| Clinical Site | Charleston | South Carolina | 29425 | — |
| Clinical Site | Dallas | Texas | 75246 | — |
| Clinical Site | Dallas | Texas | 75390-8575 | — |
| Clinical Site | San Antonio | Texas | 78218 | — |
| Clinical Site | Norfolk | Virginia | 23502 | — |
| Clinical Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06768671, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2026 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06768671 live on ClinicalTrials.gov.